NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps

Today's Daily Dose brings you news about Passport Health Plan failing to secure a new Medicaid managed care contract; Gilead's Remdesivir trial results in COVID-19 patients; Iterum missing trial goals in SURE2 study; Ocugen pulling the plug on ocular Graft vs. Host Disease; Novus' disappointing results in acute otitis media study.

from RTT - Biotech https://ift.tt/2ZXL6kp
via IFTTT